Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Department of Cardiology, Angiology and Intensive Care, Klinikum Hildesheim, Hildesheim, Germany.
Liver Int. 2017 Dec;37(12):1852-1860. doi: 10.1111/liv.13517. Epub 2017 Jul 28.
BACKGROUND & AIMS: Biliary tract cancer is a rare tumour entity characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival.
Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analysed. A prognostic model defining three prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centres.
Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) as compared to patients with non-resectable tumours (9.1 months; n=329, P<.0001). Based on univariable and multivariable analyses of clinical data, a prognostic model was created using variables available before treatment. Those were age, metastasis, C-reactive protein (CRP), international normalized ratio (INR) and bilirubin. The prognostic score distinguished three groups with a median OS of 21.8, 8.6 and 2.6 months respectively. The validation cohort had a median OS of 20.2, 14.0 and 6.5 months respectively. The prognostic impact of the score was independent of the tumour site and of treatment procedures.
Here, we identified prognostic factors and propose a prognostic score to estimate survival, which can be applied to all patients independent of tumour site and before initial treatment. Further validation in prospective trials is required.
胆道癌是一种罕见的肿瘤实体,预后较差。我们旨在确定预后因素并创建一个预后评分来估计生存。
分析了来自汉诺威医学院的训练集的 569 名患者(2000 年至 2010 年接受治疗)的临床数据。从 Cox 回归分析中得出了定义三个预后风险组的预后模型。该评分应用于来自四个德国中心的 557 名独立患者队列中,并进行了验证。
中位总生存期(OS)为 14.5 个月。如果进行了完全切除,患者的 OS 显著改善(23.9 个月;n=242),与无法切除肿瘤的患者相比(9.1 个月;n=329,P<.0001)。基于临床数据的单变量和多变量分析,创建了一个使用治疗前可用变量的预后模型。这些变量包括年龄、转移、C 反应蛋白(CRP)、国际标准化比值(INR)和胆红素。预后评分将患者分为三组,中位 OS 分别为 21.8、8.6 和 2.6 个月。验证队列的中位 OS 分别为 20.2、14.0 和 6.5 个月。评分的预后影响独立于肿瘤部位和治疗程序。
在这里,我们确定了预后因素,并提出了一个预后评分来估计生存,该评分可应用于所有患者,而与肿瘤部位和初始治疗无关。需要进一步在前瞻性试验中验证。